Down-regulation of SOCS6: an unfavorable prognostic factor for gastrointestinal stromal tumor proven by survival analysis

Jun Ouyang,Xiaofang Lu,Xinhua Zhang,Tailai An,Yan Wang,Changhua Zhang,Yawei Zhang,Xiaokun Wang

doi:10.1186/s13000-021-01172-6

Abstract

BackgroundMany studies reporting that down-regulation of SOCS6 plays vital roles in promoting progression of malignant tumors have been published. The present study was performed to evaluate whether SOCS6 was significantly associated with prognosis of GIST patients.MethodsImmunohistochemical staining was accomplished to evaluate the expression levels of SOCS6 among GIST patients. The impacts of SOCS6 expression on overall survival (OS) and recurrence-free survival (RFS) of GIST patients were assessed by Cox proportional hazard regression model analysis and Kaplan-Meier curve analysis.ResultsIt was demonstrated that the expression level of SOCS6 was significantly associated with tumor size (P=0.001). Then according to Kaplan-Meier curve analysis, low expression of SOCS6 was significantly correlated with worse OS and RFS of GIST patients. Ultimately, it was revealed by Cox proportional regression model analysis that low expression of SOCS6 was an independent predictive factor for OS and RFS.ConclusionsLow expression of SOCS6 was an independent prognostic factor for GIST, suggesting its potential as a novel biomarker predicting survival of GIST patients.

Highlights

Many studies reporting that down-regulation of suppressor of cytokine signaling 6 (SOCS6) plays vital roles in promoting progression of malignant tumors have been published
The annual incidence of gastrointestinal stromal tumor (GIST) is 10/1,000,000 [2]. It has been revealed by genomic sequencing that activated mutations of receptor protein tyrosine kinase (RPTKs) or plateletderived growth factor receptor-α(PDGFRA) occur in approximately 85-90% of GISTs [3]
The application of receptor kinase KIT and PDGFRA inhibitor could efficiently control the progression of 80-90% GISTs, about 50% of GIST patients experience secondary drug resistance within 2 years [4, 5]

Summary

Introduction

Many studies reporting that down-regulation of SOCS6 plays vital roles in promoting progression of malignant tumors have been published. The present study was performed to evaluate whether SOCS6 was significantly associated with prognosis of GIST patients. The annual incidence of GIST is 10/1,000,000 [2]. It has been revealed by genomic sequencing that activated mutations of receptor protein tyrosine kinase (RPTKs) or plateletderived growth factor receptor-α(PDGFRA) occur in approximately 85-90% of GISTs [3]. The application of receptor kinase KIT and PDGFRA inhibitor could efficiently control the progression of 80-90% GISTs, about 50% of GIST patients experience secondary drug resistance within 2 years [4, 5]. Seeking more biomarkers associated with prognosis and clinicopathological features of GISTs is still a meaningful work for us

Methods

Results

Conclusion